therapeutic advances, 5-year mortality remains as high as 20%. 2 Risk stratification in dilated cardiomyopathy therefore constitutes a crucial part of patient management with implications for surveillance, treatment, and outcome. Currently, risk stratification is heavily dependent on the assessment of left ventricular ejection fraction (LVEF), as exemplified by its use as the key determinant of device implantation. 3 Although LVEF is an important prognostic factor in dilated cardiomyopathy, 4, 5 effective risk stratification remains challenging, particularly with respect to SCD. 6, 7 Most patients who experience SCD do not have severely reduced LVEF, and many patients with significant impairment of LVEF may still be at low risk for SCD. 7, 8 Identification of better independent prognostic factors is necessary to enable clinicians to more accurately stratify risk in patients with dilated cardiomyopathy and tailor management accordingly.
Attention has recently focused on whether detection of myocardial replacement fibrosis may assist with risk stratification in dilated cardiomyopathy. Fibrosis is associated with contractile impairment, 9, 10 and provides a substrate for ventricular reentrant arrhythmia. 11, 12 Late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR) imaging enables identification and quantification of myocardial replacement fibrosis in vivo. 13, 14 Approximately 30% of patients with dilated cardiomyopathy have a characteristic midwall pattern of replacement fibrosis on LGE-CMR. 13, 15 Although several studies have suggested that midwall fibrosis may predict adverse outcomes in patients with dilated cardiomyopathy, [16] [17] [18] [19] the true prognostic value of midwall fibrosis with respect to mortality and SCD is unknown. Therefore, we prospectively evaluated whether midwall fibrosis predicts mortality, independently of LVEF and other established prognostic factors, in a large cohort of consecutive patients with dilated cardiomyopathy during a long follow-up period. Second, we assessed if midwall fibrosis was an independent predictor of SCD risk and major HF events.
METHODS

Patients
We performed a prospective, longitudinal study of the prognostic value of midwall fibrosis in a cohort of consecutive patients with dilated cardiomyopathy who were referred to the Royal Brompton Hospital in London, England, for CMR between November 2000 and December 2008. Eligible patients had a diagnosis of dilated cardiomyopathy, in accordance with the criteria of the World Health Organization/ International Society and Federation of Cardiology, 20 of at least 6 months' duration. Prior to inclusion, the diagnosis of dilated cardiomyopathy was confirmed by CMR on the basis of (1) increased left ventricular enddiastolic volume indexed to body surface area and reduced LVEF compared with published reference ranges normalized for age and sex 21 ; and (2) absence of subendocardial LGE indicative of previous myocardial infarction. 13 All patients provided written informed consent. The study was approved by the Royal Brompton Hospital ethics committee.
CMR Image Acquisition
Cardiovascular magnetic resonance imaging was performed using a 1.5-T scanner (Siemens Sonata/Avanto) and a standardized protocol. Cine images were acquired with a steady-state, free-precession sequence in long-axis planes and contiguous short-axis slices from the atrioventricular ring to the apex as previously described. 21 Ten minutes after intravenous injection of 0.1 mmol/kg of gadolinium -contrast agent (gadopentetate dimeglumine or gadobutrol, Schering), LGE images were obtained using an inversion-recovery gradient echo sequence in identical long-axis and short-axis planes. Inversion times were optimized to null normal myocardium, and images were repeated in 2 separate phase-encoding directions to exclude artifacts. 16 
Image Analysis
Left ventricular volumes, ejection fraction, and mass were measured using dedicated software (CMRtools, Cardiovascular Imaging Solutions). 21 Left ventricular volumes and mass were indexed to body surface area. The presence and location of midwall fibrosis were assessed by 2 independent expert readers (E.D.P. and M.R.D.) who were blinded to all clinical data. Midwall fibrosis was only considered present if the area of enhancement was confined to intramural and/or subepicardial layers, 22 visible in both phaseencoding directions and in 2 orthogonal views. A third blinded reader (F.A.) adjudicated in cases in which there was disagreement (n = 10). The extent of midwall fibrosis was quantified by a single experienced operator as a percentage of left ventricular mass using the full-width half-maximum technique and semiautomated software (CMR42, Circle Cardiovascular Imaging Inc). 
Follow-up and End Points
Follow-up was performed until December 2011. All events were adjudicated by the consensus of an independent committee blinded to the CMR results. Mortality status was verified from the UK National Strategic Tracing Service at 6 monthly intervals. Cause of death was established from a combination of death certification, postmortem data when available, communication with the patients' primary care physicians and cardiologists, and review of medical records for patients who died while hospitalized.
All patients were followed up for nonfatal events by telephone, postal questionnaire, or both at 6-month intervals. The patients' primary care physician and cardiologist were contacted every 6 months to facilitate review of all correspondence documenting outpatient clinic attendance or hospitalization during the follow-up period. After hospitalization, the medical records were examined to document the reason for admission and inpatient course. There were 17 patients lost to follow-up and therefore not included in the analyses.
The predefined primary end point was all-cause mortality. The principal secondary end point was a composite of cardiovascular mortality (SCD, HF, stroke, or thromboembolic event) or cardiac transplantation. Two additional secondary end points were prespecified: an arrhythmic composite end point of SCD or aborted SCD and a HF composite end point of HF death, unplanned HF hospitalization, or cardiac transplantation. Mode of death was classified according to a modified Hinkle-Thaler system. 24 Sudden cardiac death was defined as unexpected death either within 1 hour of cardiac symptoms in the absence of progressive cardiac deterioration, during sleep, or within 24 hours of last being seen alive. Heart failure death was defined as death associated with unstable, progressive deterioration of pump function despite active therapy. Aborted SCD was diagnosed in patients who received an appropriate implantable cardioverter-defibrillator (ICD) shock for ventricular arrhythmia, or had a nonfatal episode of ventricular fibrillation or spontaneous sustained ventricular tachycardia (Ͼ30 seconds in duration) causing hemodynamic compromise and requiring cardioversion. Heart failure hospitalization was categorized in patients admitted to the hospital with signs and symptoms of decompensated HF requiring treatment with an intravenous HF medication (diuretics, vasodilators, or inotropic agents). Patient data were censored at the time of any cardiac transplantation. For composite end points, only the first event for each patient was included in the analysis.
Statistical Analysis
Baseline characteristics, available for all participants, grouped by the dichotomous presence or absence of midwall fibrosis, are presented as frequency (percentage) for categorical data and mean (standard deviation) for continuous data unless otherwise stated. Comparison between groups was made using the 2 or Fisher exact tests for categorical variables and unpaired t tests for continuous variables. Survival curves were generated by the Kaplan-Meier method and compared by the logrank test. Event times were measured from the date of CMR study. A univariate Cox proportional hazards model was used to test the association between the end points and baseline covariates, with results presented as hazard ratios (HRs) with 95% confidence intervals. To determine whether midwall fibrosis was independently associated with outcome, multivariable analysis was performed with a forwardselection modeling process.
For each end point, 2 multivariate models were constructed based on inclusion of midwall fibrosis as a categorical (presence or absence) or continuous (percentage extent) variable. The proportional hazards assumption was tested and verified for each covariate. The predicted risk of each end point at 5 years was estimated from a Cox proportional hazards model that contained LVEF alone or LVEF combined with the presence or absence of midwall fibrosis. This was derived by first running a Cox model to obtain the baseline survival function at 5 years expressed as S0 (5) . A risk score for each value of LVEF, with or without midwall fibrosis, was calculated by multiplying the observed value for the model parameter by its corresponding coefficient from the Cox model. The estimated probability of observing an event at 5 years was then calculated using the formula: P(5) = 1ϪS0(5) ϫ exp(risk score). Reclassification of patient risk was determined using net reclassification improvement for all-cause mortality and the arrhythmic composite end point. 25 For each patient, the predicted overall risk of an adverse event was determined on the basis of a model using LVEF alone, and the relative improvement in patient reclassification associated with midwall fibrosis status (presence or absence) was then assessed. For all-cause mortality, reclassification was examined using the thresholds of 0%-5%, 5%-10%, 10%-20% and 20% or greater to stratify level of risk. For the arrhythmic composite end point, a risk threshold of 15% was used to stratify patients into high-and low-risk categories.
All statistical analyses were conducted using Stata version 12 (StataCorp). A 2-tailed P value of less than .05 was considered significant. For the comparison of those with vs those without midwall fibrosis, there was 90% power to detect a significant difference in mortality.
RESULTS
Study Population
A total of 489 patients met the enrolment criteria (FIGURE 1). Seventeen patients (3.5%) were lost to follow-up, resulting in a final cohort of 472 patients. Of these 472 patients, 101 patients were included in an earlier investigation, 16 and are reported herein with extended follow-up. The mean (SD) LVEF was 37% (13%) (range: 10%-59%). Significant coronary artery disease was excluded by angiography in 348 patients (74%) and stress imaging studies in 52 patients (11%). The remaining 72 patients (15%) were aged 40 years or younger, had no history of angina, and 1 or 0 risk factors for coronary artery disease. Patients were prospectively followed up for a median duration of 5.3 years (range, 31 days to 11.0 years), representing 2557 patient-years of followup. Midwall fibrosis was present in 142 patients (30%). The median extent of midwall fibrosis was 2.5% (interquartile range, 1.2%-4.8%; range, 0.4%-24.4%). Patients with midwall fibrosis were more likely to be male, have a history of malignant ventricular arrhythmia, have lower systolic and diastolic blood pressure levels, and have more symptomatic HF coupled with higher loop diuretic and aldosterone antagonist treatment rates compared with patients without midwall fibrosis (TABLE 1). The CMR measurements re- 
Histological Correlation
In 7 patients with midwall fibrosis, the hearts were explanted following death (n=3) or cardiac transplantation (n=4) and underwent detailed histopathological examination (eMethods at http: //www.jama.com). In all cases, there was excellent agreement between the location and pattern of midwall fibrosis from the in vivo CMR scan and regions of replacement fibrosis seen in the explanted hearts (FIGURE 2). The hearts of 9 patients with no midwall fibrosis on CMR, who either died (n=7) or underwent transplantation (n=2), were also reviewed. Histopathological assessment of these specimens revealed no areas of replacement fibrosis (Figure 2 ).
Primary End Point: All-Cause Mortality
During the follow-up period, 73 deaths were recorded. Overall, 38 of 142 patients with midwall fibrosis (26.8%) reached the primary end point compared with 35 of 330 patients without 
AREA OF DETAIL
A, Premortem late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR) demonstrated a near-circumferential pattern of midwall LGE (yellow arrow) in the anterior, septal, inferior, and inferolateral segments at midventricular level. B, Picrosirius red staining in the corresponding postmortem macroscopic short-axis section revealed a prominent linear band of collagen (blue arrows), which mirrored the distribution of LGE on CMR. C, Microscopic examination confirmed the presence of extensive replacement fibrosis (blue arrows) in an area of staining seen on the macroscopic section (area of detail in part B); magnificationϫ300. D, On LGE-CMR performed prior to cardiac transplantation, there were no areas of LGE. E, Following explantation, macroscopic assessment revealed no detectable regions of collagen with Picrosirius red stain. F, Microscopic section from the septal midwall (area of detail in part E) showed small amounts of perivascular fibrosis (blue arrow) but no replacement fibrosis; magnificationϫ300. The macroscopic images (B and E) were recomposited from 156 overlapping digital images taken at ϫ100 magnification with an Olympus digital microscope camera. (TABLE 3) . Other covariates that were found to be independently associated with all-cause mortality in the multivariable models were LVEF, age, heart rate, New York Heart Association functional class, and systolic blood pressure.
Cardiovascular Mortality or Cardiac Transplantation
Of the 73 deaths, the principal cause was cardiovascular in 58 patients (79% Time, y Event-Free Survival, % Log-rank P <.001
Log-rank P <.001
Log-rank P <.001 Figure 3C and Figure 3D and (Table 4) .
Incremental Prognostic Value of Midwall Fibrosis
Informationregardingthepresenceorabsence of midwall fibrosis made a sizeable difference to the risk profile of patients across the spectrum of LVEF for all end points (FIGURE 4) . For example, a patient with an LVEF of 35% in our cohort had a risk of death by 5 years of 12.7% (95% CI, 6.8%-23.0%). When midwall fibrosis status was added to the risk model, the risk of death for a patient with an LVEF of 35% and no midwall fibrosis decreased to 9.4% (95% CI, 5.0%-17.5%), while those with midwall fibrosis now had a predicted risk of death of 19.9% (95% CI, 10.8%-35.0%).
Risk Reclassification
Reclassification of risk was assessed separatelyforall-causemortality(TABLE5)and the arrhythmic composite end point ( 
FIBROSIS AND PROGNOSIS IN DILATED CARDIOMYOPATHY
COMMENT
We found that both the presence and extent of midwall replacement fibrosis were associated with an increased likelihood of all-cause mortality in dilated cardiomyopathy. This association was independent of LVEF and other established prognostic factors in multivariable analysis. After controlling for LVEF and other significant covariates, the adjusted HRs for patients with midwall fibrosis were 2.43 (PϽ .001) for all-cause mortality and 3.22 (PϽ.001) for cardiovascular death or cardiac transplantation. The presence and extent of midwall fibrosis were also significant independent predictors of the secondary composite outcomes, SCD or aborted SCD, and HF death, HF hospitalization, or cardiac transplantation. Midwall fibrosis provided incremental prognostic value across the range of LVEF observed in our cohort. The addition of midwall fibrosis to LVEF resulted in significant improvements in risk reclassification for both all-cause mortality and the arrhythmic composite. Our findings suggest that detection and quantification of midwall fibrosis by LGE-CMR may represent useful markers for the risk stratification of death, ventricular arrhythmia, and HF for patients with dilated cardiomyopathy.
The histological basis for midwall LGE in dilated cardiomyopathy is focal replacement fibrosis, which is seen at autopsy in up to one-third of patients with dilated cardiomyopathy, 27 a prevalence which mirrors that of midwall fibrosis on LGE-CMR. 13 Replacement fibrosis refers to reparative microscopic scarring that follows myocyte death. 10, 27 In keeping with previous reports, [16] [17] [18] patients with midwall fibrosis exhibited a greater degree of left ventricular dilatation and systolic impairment compared with patients without midwall fibrosis. Despite the close relationship between midwall fibrosis and ventricular remodeling, the presence of midwall fibrosis provided prognostic information that was independent of left ventricular parameters and incremental to LVEF. Midwall fibrosis retained its prognostic significance when assessed as a continuous variable, suggesting that not only the presence but also the burden of replacement fibrosis is an important determinant of outcome.
These findings support previous studies that have suggested that midwall fibrosis may be a helpful prognosticator in dilated cardiomyopathy. Early work from our group 16 showed that midwall fibrosis was the only independent predictor of a primary composite of death and cardiovascular hospitalization in 101 patients with dilated cardiomyopathy compared with standard left ventricular prognostic parameters. Two further studies have since demonstrated that midwall fibrosis appears to predict adverse outcome based on a composite of cardiovascular death, HF hospitalization, or appropriate ICD shock. 17, 18 Although these studies have provided valuable insight into the potential prognostic implications of midwall fibrosis in patients with dilated cardiomyopathy, they were limited by small sample sizes of between 56 and 184 patients, short follow-up periods (mean/median follow-up of 1.4-1.9 years), and reliance on broad composite primary end points.
More recently, subgroup analysis of a mixed HF cohort preselected for CRT, has suggested that midwall fibrosis predicts cardiovascular death or transplantation among patients with dilated cardiomyopathy. 19 However, the low event rate (11 index events) in this study meant that there were insufficient data to accurately assess the prognostic significance of midwall fibrosis, controlling for all potentially confounding variables in multivariable analysis, in the dilated cardiomyopathy subgroup. As a result, the independent prognostic value of midwall fibrosis and its relationship to mortality and SCD have thus far remained open to question.
Current assessment of prognosis in patients with dilated cardiomyopathy is primarily based on LVEF, which has long been recognized as a strong predictor of mortality. 4, 5 However, although mortality in patients with dilated cardiomyopathy increases with decreasing LVEF, this relationship is weaker in patients with severe systolic impairment. 28 A significant proportion of patients with severe systolic impairment at initial evaluation respond favorably to medical therapy with improvements in left ventricular functional indices. 29 Therefore, in patients with severely impaired left ventricular function, prediction of outcome purely on the basis of LVEF is difficult. Conversely, in patients with mild or moderate left ventricular systolic dysfunction, LVEF yields limited predictive value and yet such patients are still prone to substantial morbidity and mortality. 30 In the present study, detection of midwall fibrosis offered incremental prognostic information across the entire range of LVEF for all end points. The use of LGE-CMR may not only enable more reliable risk stratification of patients with dilated cardiomyopathy and severe left ventricular impairment, but also facilitate identification of high-risk patients with milder degrees of left ventricular dysfunction who are currently overlooked by assessment of global left ventricular function alone. Further study of patients stratified by LVEF is required to substantiate this.
In our study, patients with midwall fibrosis had worse prognosis despite higher implantation rates of ICD and CRT combined with a defibrillator, further emphasizing the negative prognostic implications of midwall fibrosis. Even though device implantation is known to improve outcome in dilated cardiomyopathy, [31] [32] [33] selection of patients for prophylactic defibrillator implantation is particularly problematic. Current guidelines for primary prevention of SCD in patients with dilated cardiomyopathy recommend defibrillator implantation in patients with New York Heart Association functional class II/III and a LVEF of less than 35%. 34, 35 However, based on such guidelines, the annual rate of appropriate defibrillator discharge is only 5.1%; consequently, the majority of patients never receive an appropriate therapy. 32, 36 Although SCD is less frequent in patients who do not meet LVEF criteria for defibrillator insertion, the proportion of SCD to all-cause mortality is higher in this group. 37 It is therefore increasingly recognized that LVEF lacks sensitivity and specificity for predicting SCD. Moreover, up to 1 in 5 patients with a prophylactic defibrillator will experience 1 or more inappropriate shocks within the first few years of implantation, with detrimental effects on mortality, HF progression, and psychological well-being. [38] [39] [40] Defibrillator implantation additionally carries a significant cost burden 39, 41 and risk of procedural complications. 32, 39 Improved risk stratification techniques for SCD in patients with dilated cardiomyopathy are therefore required to allow accurate identification of those patients who will maximally benefit from devices.
Although the mechanisms underlying SCD in patients with dilated cardiomyopathy are poorly characterized, there is emerging evidence to suggest that myocardial fibrosis forms the substrate for ventricular arrhythmias due to scar-related reentry. 11, 12 This observation is supported by the findings of our study in which patients with midwall fibrosis had a 4-fold increase in the risk of the secondary composite of SCD or aborted SCD (HR, 4.61 [95% CI, 2.75-7.74]; PϽ.001). In the multivariable analysis, the presence and extent of midwall LGE were strongly associated with the arrhythmic composite end point, even allowing for conventional SCD risk factors such as previous malignant ventricular arrhythmia and LVEF. While there is contention regarding whether appropriate ICD discharge equates to aborted SCD, 39 midwall fibrosis still remained a significant independent predictor of arrhythmic outcome following exclusion of ICD therapy from the composite.
In the net reclassification improvement analysis, the addition of midwall fibrosis to LVEF was associated with improved risk stratification for SCD. There is no formal consensus regarding the level of SCD risk at which ICD implantation is justified in patients with dilated cardiomyopathy. In the present study, we selected a 15% SCD risk threshold to define high-and low-risk categories to direct ICD implantation, guided by the SCD event rates in the Marburg Cardiomyopathy Study. 42 Based on the incremental information provided by LGE-CMR in our cohort, of the 65 patients who reached the SCD composite, an additional 12 patients (18.5%) would now undergo ICD implantation. In addition, of the 407 patients who did not experience the SCD outcome, 43 patients would now avoid ICD implantation (10.6%). The use of LGE-CMR therefore improves detection of patients with dilated cardiomyopathy at high risk for SCD who are currently missed by stratification using LVEF. At the same time, LGE-CMR reduces the number of patients who would undergo ICD implantation without subsequently experiencing a SCD event. These data suggest that LGE-CMR may refine the SCD risk estimate in dilated cardiomyopathy, raising the possibility that this information could guide ICD implantation with po-tential implications for public health and resource use.
